ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on overcoming resistance in cancer. It develops precision medicines intended to make existing cancer therapies more effective and durable. Its clinical-stage candidates include rinzimetostat (ORIC-944), an EED/PRC2 inhibitor being developed for prostate cancer, and enozertinib, a brain-penetrant inhibitor targeting EGFR and HER2 exon 20 and EGFR atypical mutations across genetically defined cancers, alongside additional resistance-focused medicines.